What caused KTTA's EPS to surge in Q4 2022?

Pasithea Therapeutics Corp. (KTTA) did not report an EPS surge in Q4 2022. In fact, the company's latest report period is for Q4 2024, and no EPS data was found for that period. Therefore, it is not possible to determine what caused the EPS to surge in Q4 2022, as the data is not available. However, it is important to note that Pasithea Therapeutics has been focused on developing treatments for central nervous system disorders and RASopathies, and has made progress in its clinical trials for its lead product candidate, PAS-004. The company's research and development efforts may have contributed to any positive financial results, although specific details on the causes of any EPS surge would be needed to confirm this.